StockData
Onconetix, Inc. logo

Onconetix, Inc. (ONCO) stock

ONCONasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 3/30
$3.15+0.15 (+5.00%)

Close on Nov 18, 2026Market cap $12.44MP/E –Yield –

Onconetix r&d expenses

Research and development expenses are spending on new products and technology.

Onconetix's R&D Expenses for the twelve months ending Dec 31, 2022 was $4.13M, up 211.7% year over year. For fiscal 2024 it was $154.36K, down 92.1% from the year before.

Annual r&d expenses

PeriodPeriod endValueChange
FY2024Dec 31, 2024$154.36K-92.1%
FY2023Dec 31, 2023$1.95M-52.8%
FY2022Dec 31, 2022$4.13M+211.7%
FY2021Dec 31, 2021$1.33M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q1 FY2025Mar 31, 2025$24.46K-98.0%
Q3 FY2024Sep 30, 2024$109.37K-90.7%
Q1 FY2024Mar 31, 2024$48.96K-96.2%
Q3 FY2023Sep 30, 2023$219.24K-51.8%
Q4 FY2022Dec 31, 2022$1.21M+175.7%
Q3 FY2022Sep 30, 2022$1.18M+335.5%
Q2 FY2022Jun 30, 2022$1.29M+144.3%
Q1 FY2022Mar 31, 2022$455.09K+415.8%
Q4 FY2021Dec 31, 2021$437.33K–
Q3 FY2021Sep 30, 2021$269.93K–
Q2 FY2021Jun 30, 2021$529.54K–
Q1 FY2021Mar 31, 2021$88.24K–

More Onconetix figures

See a number that looks wrong?